MICHELLE RENEE GRIFFIN
CIK 1229765 · CFO · last filed 2026-06-29
MICHELLE RENEE GRIFFIN is a CFO who has filed 57 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for ADPT, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$5.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $397.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$397.7K
8
57
-$5.88M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADPT | Director | 15,625 | $25.45 | $397.7K | -$5.88M | 23 | 2026-06-29 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Director | 0 | $40.39 | $0 | $0 | 5 | 2023-08-11 |
| Acer Therapeutics Inc. (ACER) Delisted | Director | — | $0.66 | — | $0 | 5 | 2023-03-16 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | Director | 14 | $0.48 | $7 | $0 | 5 | 2022-09-15 |
| Acer Therapeutics Inc. (ACERW) Delisted | Director | — | — | — | $0 | 1 | 2017-10-06 |
| ACHIEVE LIFE SCIENCES, INC. (OGXI) Delisted | CFO | — | — | — | $0 | 5 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Senior V.P. and C.O.O. | 0 | — | — | $0 | 5 | 2010-10-28 |
| ACHIEVE LIFE SCIENCES, INC. (SNUS) Delisted | Director | — | — | — | $0 | 1 | 2007-05-14 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | ADPT | Mixed | — | -$644.8K | EDGAR |
| 2026-06-25 | ADPT | Notice (144) | −52,084 | -$1.01M | EDGAR |
| 2026-03-13 | ADPT | Sell (S) | −15,394 | -$214.1K | EDGAR |
| 2026-03-11 | ADPT | Notice (144) | −15,394 | -$214.1K | EDGAR |
| 2026-03-06 | ADPT | Grant (A) | +15,625 | $0 | EDGAR |
| 2026-03-05 | ADPT | Mixed | — | -$543.4K | EDGAR |
| 2026-03-03 | ADPT | Notice (144) | −48,044 | -$774.5K | EDGAR |
| 2025-03-17 | ADPT | Sell (S) | −36,291 | -$260.9K | EDGAR |
| 2025-03-13 | ADPT | Notice (144) | −36,291 | -$260.9K | EDGAR |
| 2025-03-06 | ADPT | Notice (144) | −15,664 | -$124.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.